The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
See which stocks are posting big moves after the bell on July 22.Market Insiderread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
The deal could be announced as soon as next week, according to the report.Technologyread more
Former NFL offensive lineman Jeff Hatch, who had previously been candid about his own struggles with opioid addiction and substance abuse, pleaded guilty Friday to a drug...Politicsread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
T-Mobile is choosing to move ahead with a merger with Sprint even though it will prop up Dish Network as a new, possibly disruptive fourth U.S. wireless competitor.Technologyread more
Danger is lurking in the stock market: An abrupt sell-off could be around the corner if the Federal Reserve doesn't deliver the rate cut the market expects next week, the firm...Marketsread more
China has an ambitious plan to become a global leader in innovation and technology, and that could potentially bode very well for German multinational company Merck KGaA.
The company is one of the leading names in science and technology and does business across three sectors: health care, life science and performance materials.
The latter two business units help to make Chinese companies more competitive, Merck KGaA Chairman and CEO Stefan Oschmann told CNBC on Thursday on the sidelines of the Fortune Global Forum in Guangzhou, China.
"For instance, we are working with Chinese start-ups or larger biotech companies in the manufacturing process and the research process," he said. "Or we're making materials for Chinese electronics manufacturers (and) display manufacturers."
As a result, Oschmann said, Merck KGaA is in a "very interesting place" in the rapidly developing Chinese market.
Earlier this year, industry watchers agreed that China was shedding its image as a country that copies ideas from the West to become a tech and innovation powerhouse. At least one expert said Chinese companies were increasingly innovating in more hardcore technological areas.
When asked if China was becoming stricter toward foreign companies operating within the mainland, Oschmann said he was seeing "a lot more assertiveness and that is only natural given the size of the market and the importance of China in the world economy."
He added that the Chinese government, and business partners, understand Merck's value as a partner in helping to upgrade their industries in areas such as biotechnology and electronics.
One common gripe many foreign companies have when it comes to doing business in China is around intellectual property theft. But recently, Beijing has cracked down on intellectual property rights violations including corporate espionage and counterfeiting of well-known brands.
"We see that China is becoming much more positive toward intellectual property protection," Oschmann said, adding that particularly was the case in the pharmaceutical sector. He added that, while China's IP legislation was "very, very good" in theory, the problem lies with enforcing it against those violating the laws.
"That's where the Chinese government needs to evolve the system. It must be more predictable. Companies must have a more predictable environment when it comes to enforcing IP," he said, adding that he thinks the state of affairs is moving in the right direction.
On another note, Oschmann addressed the potential sale of Merck's consumer health unit. Reuters reported late last week, citing sources, that Swiss food giant Nestle and private equity owners of German drug firm Stada were both preparing tentative bids for that business.
Oschmann said Merck's consumer health business is performing very well: "Last quarter, we had 11 percent topline growth," he said, adding that the dynamics of the market were changing rapidly.
"Size has become so important in consumer health and we believe we're not the best owner of that business going forward," he added. Oschmann said he expects that a deal could potentially be signed by the second quarter of next year, although closing an agreement would take a longer time due to regulatory approval process.